Reviva Pharmaceuticals Holdings Inc (RVPHW) - Total Liabilities
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc (RVPHW) has total liabilities worth $9.78 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RVPHW cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Reviva Pharmaceuticals Holdings Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Reviva Pharmaceuticals Holdings Inc balance sheet assets.
Reviva Pharmaceuticals Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
US Solar Fund PLC
LSE:USFP
|
UK | GBX820.00K |
|
Prairie Lithium Limited
AU:PL9
|
Australia | AU$4.03 Million |
|
Lion Financial Group Limited
NASDAQ:LGHLW
|
USA | $29.17 Million |
|
Advent Technologies Holdings Inc
NASDAQ:ADNWW
|
USA | $24.46 Million |
|
Kardan NV
TA:KRNV
|
Israel | ILA721.20 Million |
|
Arko Corp
NASDAQ:ARKOW
|
USA | $3.21 Billion |
|
Ordinary Fully Paid Deferred Settlement
AU:1TTDB
|
Australia | AU$243.99K |
Liability Composition Analysis (2018–2024)
This chart breaks down Reviva Pharmaceuticals Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Reviva Pharmaceuticals Holdings Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Reviva Pharmaceuticals Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Reviva Pharmaceuticals Holdings Inc (2018–2024)
The table below shows the annual total liabilities of Reviva Pharmaceuticals Holdings Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.69 Million | -18.30% |
| 2023-12-31 | $17.98 Million | +70.78% |
| 2022-12-31 | $10.53 Million | +287.46% |
| 2021-12-31 | $2.72 Million | -17.56% |
| 2020-12-31 | $3.30 Million | -51.62% |
| 2019-12-31 | $6.81 Million | +11.96% |
| 2018-12-31 | $6.09 Million | -- |
About Reviva Pharmaceuticals Holdings Inc
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, i… Read more